Price T Rowe Associates Inc. MD Sells 2,121,474 Shares of Regulus Therapeutics Inc. (NASDAQ:RGLS)

Price T Rowe Associates Inc. MD decreased its holdings in Regulus Therapeutics Inc. (NASDAQ:RGLS - Free Report) by 98.6% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 29,597 shares of the biopharmaceutical company's stock after selling 2,121,474 shares during the period. Price T Rowe Associates Inc. MD's holdings in Regulus Therapeutics were worth $47,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in RGLS. Barclays PLC increased its holdings in shares of Regulus Therapeutics by 285.2% during the 3rd quarter. Barclays PLC now owns 84,477 shares of the biopharmaceutical company's stock worth $132,000 after acquiring an additional 62,549 shares during the last quarter. JPMorgan Chase & Co. boosted its position in Regulus Therapeutics by 193.4% during the third quarter. JPMorgan Chase & Co. now owns 78,972 shares of the biopharmaceutical company's stock worth $124,000 after purchasing an additional 52,059 shares during the period. Renaissance Technologies LLC increased its holdings in shares of Regulus Therapeutics by 20.5% in the fourth quarter. Renaissance Technologies LLC now owns 117,100 shares of the biopharmaceutical company's stock valued at $185,000 after purchasing an additional 19,900 shares during the last quarter. Finally, PEAK6 LLC bought a new position in shares of Regulus Therapeutics in the fourth quarter valued at about $95,000. 92.38% of the stock is owned by institutional investors and hedge funds.

Regulus Therapeutics Trading Down 0.1%

NASDAQ RGLS traded down $0.01 during trading on Thursday, reaching $7.91. The company's stock had a trading volume of 696,462 shares, compared to its average volume of 893,817. The firm has a 50 day moving average price of $3.80 and a 200 day moving average price of $2.23. Regulus Therapeutics Inc. has a 12 month low of $0.83 and a 12 month high of $8.20. The firm has a market capitalization of $547.64 million, a price-to-earnings ratio of -7.39 and a beta of 0.49.

Regulus Therapeutics (NASDAQ:RGLS - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.15) earnings per share for the quarter, beating analysts' consensus estimates of ($0.29) by $0.14. On average, equities analysts forecast that Regulus Therapeutics Inc. will post -0.88 EPS for the current fiscal year.

Analysts Set New Price Targets

Several analysts recently commented on RGLS shares. HC Wainwright reaffirmed a "buy" rating and set a $10.00 target price on shares of Regulus Therapeutics in a report on Friday, March 14th. Jones Trading restated a "hold" rating and set a $7.00 price objective (down previously from $8.00) on shares of Regulus Therapeutics in a report on Wednesday, April 30th. Wall Street Zen started coverage on Regulus Therapeutics in a research report on Sunday. They issued a "sell" rating on the stock. Leerink Partnrs lowered Regulus Therapeutics from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, April 30th. Finally, Leerink Partners reissued a "market perform" rating and set a $7.00 price target on shares of Regulus Therapeutics in a report on Wednesday, April 30th. One analyst has rated the stock with a sell rating, five have issued a hold rating and two have given a buy rating to the stock. According to MarketBeat, Regulus Therapeutics has a consensus rating of "Hold" and a consensus price target of $8.50.

Regulus Therapeutics Company Profile

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.